Sixty-four percent of patients (596) were undergoing surveillance because of their family history of pancreatic cancer, 329 (35.6%) patients had a known pathogenic germline variant (with or without family history), including 149 (45.3%) with a BRCA2, 44 (13.8%) with an ATM, and 45 (13.7%) with a BRCA1 variant. The gene discussed is BRCA2; the disease is familial pancreatic carcinoma.